MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd MXC

Dividend Summary



There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Status
Type
Per share
Declaration date
Ex-div date
Pay date

Enter the number of MGC Pharmaceuticals Ltd shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for MGC Pharmaceuticals Ltd
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for MGC Pharmaceuticals Ltd
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no MGC Pharmaceuticals Ltd dividends.
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 0.0c
0%
2013 0.0c
0%
2014 0.0c
0%
2015 0.0c
0%
2016 0.0c
0%
2017 0.0c
0%
2018 0.0c
0%
2019 0.0c
0%
2020 0.0c
0%
2021 0.0c
0%
2022 Sign Up Required

MGC Pharmaceuticals Ltd Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on 18 November 2021
52 Week Low
0.0% on 18 November 2021
Next Ex-Div-Date Countdown
Sign Up Required

About MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd is an Australia-based biopharma company. The Company is primarily focused on the development and supply of standardized phytomedicines to patients globally. It has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy, and CogniCann, in a Phase II trial for symptomatic relief of Dementia. Its products also include CannEpil, MP 100, MP 1:30, MP 1:1, MP 15:1 and MP 25T. The Company is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. It has a product offering targeting two medical conditions, which include epilepsy and dementia. The Company’s wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd and Medicinal Cannabis Clinics Pty Ltd.

Sector
Pharmaceuticals & Biotechnology
Country
Australia
Share Price
AU$0.02 (yesterday's closing price)
Shares in Issue
2,230 million
Market Cap
AU$40mn
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
0
Market Indices
none
No articles found